news
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
List view / Grid view
National Institute for Health and Care Excellence (NICE)
news
Dr William van’t Hoff next NIHR Clinical Research Network Chief Executive
The next Chief Executive of the National Institute for Health Research’s Clinical Research Network has been announced as Dr William van’t Hoff.
news
NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
news
EC approves two new regimens of Keytruda for HNSCC
The European Commission has given its approval to Keytruda to treat head and neck squamous cell carcinoma as a monotherapy or in combination with a chemotherapy.
news
Hereditary angioedema treatment recommended by NICE
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
news
NICE recommends voretigene neparvovec for use on NHS
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.
news
NICE to work with GW Pharma on cannabidiol evaluation
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
news
Chief executive of NICE to leave role in 2020
Sir Andrew Dillion will be stepping down from his role as chief executive of NICE next year, after holding his position for 20 years.
news
NICE releases draft guidance for using cannabis-based medicinal products
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
news
NICE recommends Lokelma treatment for hyperkalaemia
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
news
NICE recommends risankizumab to treat severe psoriasis
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.
news
NHS to launch subscription service to encourage R&D
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
news
NICE endorses dacomitinib for treatment of lung cancer
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
news
Decision by NICE for the use of osimertinib to be appealed
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
news
NICE and Canadian Agency collaborate to offer parallel scientific advice
NICE in the UK and its counterpart - the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice...
